SpeeDx Awarded A$2.5M Grant, Inks Scandinavian Distribution Deal

Sep 18, 2017

|

NEW YORK (GenomeWeb) – Australian molecular diagnostics company SpeeDx said it has received a A$2.5 million ($2 million) grant from the New South Wales Medical Devices Fund (MDF) to support the continued rollout of its multiplex molecular diagnostic ResistancePlus MG test.

Separately, it also announced a distribution deal with Scandinavian clinical laboratory supplier Diagen.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Shift to New Variant Work

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

Victim Identified with Genetic Genealogy

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Featured White Papers

For In Vitro Diagnostic Materials: Efficacy vs. Thimerosal and Sodium Azide

Development of a Quantitative Lateral Flow Test Using Estapor Europium Microspheres

Performance of Estapor Microspheres and Hi-Flow Plus Membranes in a Lateral Flow Assay for Human Chorionic Gonadotropin (hCG)

ProClin 300 Preservative An In depth Technical Analysis

Feb

11

Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb

17

Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb

18

Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Menu

SpeeDx Awarded A$2.5M Grant, Inks Scandinavian Distribution Deal

To read the full story....

Breaking News

Bioron to Distribute GenapSys Sequencing Technology in Germany

Mobilion, Protein Metrics Partner on Ion Mobility Mass Spec Data Analysis Tools

Genomind Receives Medicare Coverage for Pharmacogenetics Test

Thermo Fisher Scientific, SPT Labtech to Comarket Sequencing Library Prep Products

BC Platforms, Finnish Researchers, Japan's Riken Partner on COVID-19 Risk Assessment

NRGene Completes $30.6M IPO

The Scan

Shift to New Variant Work

Victim Identified with Genetic Genealogy

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

Should Also Work

Featured White Papers

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

Infectious Disease Test Firm Talis Biomedical Files for IPO

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

Sponsorships